I-Mab’s pipeline pivot had a sting in the tail. Weeks after shifting its focus, the biotech said Wednesday that it has reduced its workforce by around 27% in conjunction with the pipeline ...

I-Mab, a Rockville-based global biotech company, Monday announced it was chosen to participate in one-on-one and small group meetings with investors at the Truist Securities BioPharma Symposium on Nov ...

The Daily Record is a digital-first daily news media company focused on law, government, business, recognition events, Power Lists, special products, public notices and more.

Application is based on proprietary poxvirus system that enables Hard-to-Drug Complex Proteins to be expressed at high levels in their “native conformation” so as to efficiently induce and select ...

I-Mab will present clinical updates on givastomig at the Jefferies Global Healthcare Conference and share new data at ESMO 2025. I-Mab, a U.S.-based biotech company specializing in precision ...

Monoclonal antibodies (mAbs) have revolutionized modern medicine, offering precision therapies for cancer, autoimmune disorders, infectious diseases, and numerous other advantages. The global mAb ...

Y-mAbs Therapeutics (NASDAQ:YMAB) stock peaked at $54.1 in late 2020, fueled by high hopes for its cancer treatment, Omburtamab. However, the FDA's 2020 Refusal to File and subsequent Complete ...

I-Mab Biopharma has completed its transition to a US-based biotech, focusing its efforts on a streamlined organization with a new US leadership team. The company is advancing its immunotherapeutic ...